Russell Investments Group’s Structure Therapeutics GPCR Stock Holding History

Russell Investments Group’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$516K	Sell	10,701 -15,573	-59%	-$1.07M	﹤0.01%	2488
2025 Q4	$1.83M	Buy	+26,274	New	+$1.07M	﹤0.01%	1922
2025 Q1	–	Sell	-34,671	Closed	-$940K	–	3828
2024 Q4	$940K	Buy	34,671 +2,888	+9%	+$102K	﹤0.01%	2037
2024 Q3	$1.39M	Buy	31,783 +13,196	+71%	+$510K	﹤0.01%	1876
2024 Q2	$730K	Sell	18,587 -3,125	-14%	-$128K	﹤0.01%	2083
2024 Q1	$931K	Sell	21,712 -6,681	-24%	-$282K	﹤0.01%	1999
2023 Q4	$1.16M	Buy	+28,393	New	+$1.63M	﹤0.01%	1895

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Russell Investments Group's GPCR Position: Q1 2026 in Review

Russell Investments Group reduced its Structure Therapeutics (GPCR) stake by 59% in Q1 2026, selling an estimated $1.07M and leaving 10,701 shares worth $516K. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Russell Investments Group first reported a position in GPCR in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.83M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Russell Investments Group held 10,701 shares of Structure Therapeutics worth $516K as of Q1 2026.
Russell Investments Group sold 15,573 Structure Therapeutics shares in Q1 2026, an estimated $1.07M.
Structure Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2488 holding.
Russell Investments Group first reported a position in Structure Therapeutics in Q4 2023 and has held it in 7 quarters since.
Russell Investments Group's Structure Therapeutics position peaked at $1.83M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.